Tesamorelin vs CJC-1295 (with DAC)
Tesamorelin has strong indication-specific Phase III VAT evidence; CJC-1295 mainly has early endocrine target-engagement studies.
| Attribute | Tesamorelin | CJC-1295 (with DAC) |
|---|---|---|
| Human evidence | Tesamorelin has strong evidence for its narrow HIV-associated abdominal-fat indication. A randomized HIV/NAFLD study also reduced liver fat substantially, while a small 2025 Phase II cognitive trial did not show significant between-group cognitive benefit. | Small early human studies show sustained GH and IGF-I elevation after CJC-1295 with DAC, establishing endocrine target engagement but not body-composition, recovery or anti-ageing efficacy. |
| Research focus | Excess abdominal visceral fat in adults with HIV and lipodystrophy | Growth-hormone axis research |
| Regulatory status | FDA-licensed Egrifta formulations are indicated to reduce excess abdominal fat in adults with HIV and lipodystrophy; not a general weight-loss approval. | Not FDA-approved; FDA lists CJC-1295 among substances with significant safety concerns in compounding. |
| Route / formulation | Research-market tesamorelin is not automatically equivalent to authorised Egrifta products. | CJC-1295 with DAC is not interchangeable with informal 'CJC without DAC' products. |
Why these are compared
These compounds appear in the visceral fat / gh-axis comparison evidence landscape, but they are not interchangeable. Tesamorelin is ghrh analogue peptide studied in excess abdominal visceral fat in adults with hiv and lipodystrophy; CJC-1295 (with DAC) is long-acting ghrh analogue peptide studied in growth-hormone axis research. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
Tesamorelin: Approved narrow indication with additional randomized human metabolic evidence.
CJC-1295 (with DAC): Early human pharmacology with regulator safety concerns; unapproved.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No appropriate head-to-head trial. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.